Clinical Trials
16 trialsNCT02710734 2026-05-22
Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)
Fox Chase Cancer Center
Phase 2 Completed
NCT04216290 2026-05-22
A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06770582 2026-05-22
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06388720 2026-04-13
IMGeS
National Cancer Center, Korea
Phase 2 Recruiting
NCT04172675 2026-02-24
A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
Janssen Research & Development, LLC
Phase 2 Completed
NCT07189793 2025-09-24
OHAI-NMIBC-01
First Affiliated Hospital of Wenzhou Medical University
Phase 2 Not yet recruiting
NCT05024734 2025-03-11
GAIN INST
Hospital Centre Biel/Bienne
Phase 2 Recruiting
NCT03658304 2024-11-05
Trial of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma
University of Florida
Phase 2 Completed
NCT00981656 2024-09-19
Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer
Radiation Therapy Oncology Group
Phase 2 Completed
NCT06227065 2024-01-26
POLO
University of Bern
Phase 2 Not yet recruiting
NCT03617913 2023-01-06
Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer
Mayo Clinic
Phase 2 Completed
NCT03558503 2022-09-16
OPTIMA II
UroGen Pharma Ltd.
Phase 2 Completed
NCT02070120 2020-03-19
CALIBER
Institute of Cancer Research, United Kingdom
Phase 2 Unknown
NCT02307487 2017-06-16
Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients
UroGen Pharma Ltd.
Phase 2 Completed
NCT00023842 2012-09-24
BCG With or Without Mitomycin in Treating Patients With Bladder Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00192049 2007-05-17
A Randomized Study Comparing Single Agent Gemcitabine Intravesical Therapy Versus Mitomycin C in Patients With Intermediate Risk Superficial Bladder Cancer
Eli Lilly and Company
Phase 2 Completed